Minimal Residual Disease Testing Market

• Increasing incidence of hematological malignancies

The incidence of hematological malignancies, which are cancers of the blood and bone marrow, has been increasing globally over the past few decades. This increase is thought to be due to a combination of factors, including an aging population, a change in lifestyle, and a rising number of people with weakened immune systems. Moreover, according to GLOBOCAN 2020, new cases for leukemia were 474,519, non-Hodgkin lymphoma cases were 544,352, and Hodgkin cases were 83,087. Furthermore, initiatives are having a positive impact on cancer awareness and prevention.

Global health organizations such as the World Health Organization (WHO), the Union for International Cancer Control (UICC), the World Cancer Research Fund International, and Worldwide Cancer Research are committed to continuing to raise cancer awareness and reduce the burden of cancer worldwide. Moreover, initiatives undertaken include providing information and education about cancer, supporting cancer research, advocating for cancer control policies, and empowering cancer survivors.

Therefore, rising incidences of minimal residual disease testing and growing awareness through global organization are fueling the growth of the market.

The Global Minimal Residual Disease Testing Market Industry is poised for substantial growth, with projections indicating a market value of 7.9 USD Billion by 2035. This anticipated growth reflects the increasing recognition of the importance of MRD testing in oncology, particularly for hematological malignancies. The market is expected to experience a compound annual growth rate of 11.35% from 2025 to 2035, driven by advancements in technology, rising prevalence of cancer, and growing awareness among healthcare professionals. As the industry evolves, it is likely to witness further innovations that enhance the accuracy and efficiency of MRD testing, ultimately improving patient outcomes.

Regulatory bodies are increasingly recognizing the importance of minimal residual disease testing in oncology, thereby providing support and establishing guidelines that facilitate its integration into clinical practice. The Global Minimal Residual Disease Testing Market Industry is positively influenced by these regulatory frameworks, which promote the standardization of testing protocols and ensure the reliability of results. As regulatory support continues to evolve, it is anticipated that more healthcare institutions will adopt MRD testing as a routine part of patient management. This trend is likely to contribute to the overall growth of the market, reinforcing its role in improving treatment outcomes.

Investment in cancer research is a significant driver of the Global Minimal Residual Disease Testing Market Industry. Increased funding from both public and private sectors is directed towards understanding cancer biology and developing innovative diagnostic tools. This influx of capital supports research initiatives focused on MRD testing, leading to the discovery of novel biomarkers and improved testing methodologies. As research progresses, the market is expected to expand, with projections indicating a market value of 7.9 USD Billion by 2035. The ongoing commitment to cancer research underscores the critical role of MRD testing in advancing personalized medicine and enhancing patient care.

Technological innovations play a crucial role in shaping the Global Minimal Residual Disease Testing Market Industry. The development of highly sensitive techniques, such as next-generation sequencing and flow cytometry, has revolutionized MRD detection. These advancements not only improve the precision of measurements but also reduce the time required for testing. As a result, healthcare providers are increasingly adopting these advanced methodologies, which are expected to contribute to the market's growth trajectory. The industry is projected to expand significantly, with a compound annual growth rate of 11.35% from 2025 to 2035, indicating a robust future driven by ongoing technological enhancements.

The Global Minimal Residual Disease Testing Market Industry experiences a notable surge in demand due to the increasing prevalence of hematological malignancies such as leukemia and lymphoma. As of 2024, the market is valued at approximately 2.42 USD Billion, reflecting a growing recognition of the importance of early detection and monitoring of these diseases. The ability to identify minimal residual disease allows for timely therapeutic interventions, potentially improving patient outcomes. This trend is likely to continue, as advancements in testing technologies enhance the accuracy and sensitivity of MRD testing, thereby driving further growth in the industry.

The Global Minimal Residual Disease Testing Market Industry benefits from heightened awareness among healthcare professionals regarding the significance of MRD testing in patient management. Educational initiatives and training programs are being implemented to equip clinicians with the knowledge necessary to utilize MRD testing effectively. This growing awareness is likely to lead to increased adoption rates of MRD testing in clinical practice, thereby enhancing patient care. As healthcare systems recognize the value of MRD testing in guiding treatment decisions, the industry is expected to witness substantial growth, aligning with the projected market value of 7.9 USD Billion by 2035.

By region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. In North America, the minimal residual disease testing market held the largest market share in 2022 due to the presence of major players in the US such as Adaptive Biotechnologies (US), Sysmex Inostics, Inc. (US), Arup Laboratories Inc. (US), ArcherDX, Inc. (US), and Asuragen Inc. (US). Additionally, the rising incidences of lymphoma and leukemia are driving the growth of the North America region.

As per the American Cancer Society's estimated that there were 59,610 new cases of leukemia and 23,710 deaths from leukemia in the US in 2023. Further, 20,380 cases of acute myeloid leukemia were reported in 2023.

Hence, the presence of major players in the region and increasing incidences of cancer are fostering the growth of the North American minimal residual disease testing market.

Further, the major countries studied are: The US, Canada, France, Germany, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

FIGURE 3: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, 2022 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, Market Research Future Database, and Analyst Review

The European minimal residual disease testing market accounted for the second-largest market share due to the growing geriatric population. The incidences of blood related cancers increase with increases in age. The risk of leukemia is more than 10 times higher in people over the age of 65 than in people under the age of 45. In September 2022, it has been estimated by the World Economic Forum that more than 30% of the European population are expected to be 65 or older by 2100. Thus, growing geriatric population will create greater opportunities for the Europe market during the forecast period.

Moreover, the Germany minimal residual disease testing market held the largest market in 2022, and the France minimal residual disease testing market is projected to be the fastest-growing market in the Europe region.

The Asia-Pacific minimal residual disease testing market is the fastest growing region from 2023 to 2032, owing to the growing incidence of hematological cancer, increased geriatric population, and the strategic formation to meet the demand of customers boosts Asia-Pacific region growth. For instance, October 2021, Genetron Health (China) and Jiangsu Fosun (China) started commercialization of MRD detection test in China, also promoted Seq-MRD in hematologic-focused hospitals and clinics in China. This test provides accuracy, high throughput, cost-efficiency, uniformity and fast turnaround time.

Furthermore, the China minimal residual disease testing market accounted for the largest market share in 2022, and the India minimal residual disease testing market is projected to be the fastest-growing market in the Asia-Pacific region.

The key players in the Minimal Residual Disease Testing Market are investing heavily in research and development in order to develop new and more sensitive MRD testing technologies. They are also expanding their geographic reach through product launches, contractual agreements, mergers & acquisitions, investments, and collaboration with other market players in order to make MRD testing more accessible to patients around the world.

Adaptive Biotechnologies (US) is a clinical-stage company that develops next-generation immunosequencing (NGS) platforms and products to help physicians diagnose, treat, and monitor patients with cancer and other diseases. The company has a wide range of locations in North America and Europe. Furthermore, in October 2022, Adaptive Biotechnologies (US) partnered with Epic Systems Corporation in order to integrate the clonoSEQ assay into Epic’s comprehensive electronic medical record (EMR) system.

The clonoSEQ Assay has been monitored by the US Food and Drug Administration and approved for chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and B-cell acute lymphoblastic leukemia (ALL) to detect minimal residual disease.